Shortage of Novo Nordisk's Wegovy and Ozempic drugs is resolved, FDA says
FDA to spare compounders as Novo Nordisk’s Ozempic supply begins to improve
Shortage of Novo's Wegovy and Ozempic is resolved, FDA website shows
U.S. attorneys general forum urges FDA to act against counterfeit weight loss drugs
U.S. attorneys general urge the FDA to combat counterfeit versions of weight loss drugs developed by Eli Lilly (LLY) and Novo Nordisk (NVO). Read more here.
Healio10d
FDA approves subcutaneous Merilog for glycemic control in diabetes
The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog (insulin-aspart-szjj, Sanofi-Aventis U.S.) was approved as biosimilar to Novolog (Novo Nordisk) for improving blood sugar control for individuals with the condition,
Why Novo Nordisk Stock Popped on Friday
Well, at least for Novo Nordisk's Ozempic and Wegovy. Novo Nordisk sales should be going up, and Hims & Hers Health's sales should be going down soon. This morning, the U.S. Food and Drug Administration (FDA) issued a "declaratory order" confirming the "resolution of shortages of semaglutide injection products
Hims & Hers Stock Plummets. The Wegovy Shortage Is Over.
 · 3dModern Healthcare
Hims & Hers' stock plunges as semaglutide shortage ends
The Food and Drug Administration said on Friday that the shortage of semaglutide injection products, such as Novo Nordisk's Wegovy, has been resolved. FDA's update led to renewed uncertainty for a growing group of telehealth companies such as Hims & Hers that have built businesses around offering cheaper copies of the branded medications.
Why Hims & Hers Health Stock Is Plummeting Today
Hims & Hers will no longer be able to sell generic "compounded" versions, a key driver of its recent success. The U.S. Food and Drug Administration (FDA) removed semaglutide injection products like the blockbuster drugs Ozempic and Wegovy from its shortage list.
Shortage of Novo Nordisk’s (NVO) Weight Loss Drugs Is Resolved, Says FDA
The shortage of Novo Nordisk’s (NVO) blockbuster weight loss drugs has been resolved, according to the U.S. Food and Drug Administration
FDA declares Wegovy(R) and Ozempic(R) shortage is over and that Novo Nordisk is fully meeting or exceeding nationwide demand for all doses
FDA declares Wegovy (R) and Ozempic (R) shortage is over and that Novo Nordisk is fully meeting or exceeding nationwide demand for all doses -- All doses of the only real FDA-approved semaglutide medicines are being continuously shipped,
Drug compounders sue FDA over semaglutide status: report
Makers of copycat versions of Novo Nordisk's (NVO) weight-loss drug semaglutide, also known as Ozempic and Wegovy, are suing the FDA for removing the drug from its shortage list.
Ozempic and Wegovy are no longer in shortage, FDA says
Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration said on Friday.
Becker's Hospital Review12h
FDA sets deadline to end sales of Ozempic, Wegovy copycats
Semaglutide — the key ingredient in Ozempic and Wegovy — had been in shortage since 2022. Now that supply has stabilized, state-licensed compounding pharmacies and physicians must stop selling compounded semaglutide by April 22, while outsourcing facilities have until May 22 to cease production and distribution.